Armata Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1997
Revenue	4.53	5.51	4.47	0.82	0	Upgrade
Revenue Growth (YoY)	-17.77%	23.11%	443.62%	-	-	Upgrade
Gross Profit	4.53	5.51	4.47	0.82	0	Upgrade
Selling, General & Admin	11.65	7.44	8.28	7.97	9.27	Upgrade
Research & Development	33.77	35.02	20.02	14.44	9.82	Upgrade
Other Operating Expenses	0	0	0	0	0.66	Upgrade
Operating Expenses	45.42	42.45	28.3	22.41	19.75	Upgrade
Operating Income	-40.89	-36.95	-23.82	-21.59	-19.75	Upgrade
Interest Expense / Income	2.63	0	0.06	0.63	0.93	Upgrade
Other Expense / Income	25.53	-0.03	-0.73	-0.03	-1.2	Upgrade
Pretax Income	-69.05	-36.92	-23.16	-22.18	-19.48	Upgrade
Net Income	-69.05	-36.92	-23.16	-22.18	-19.48	Upgrade
Shares Outstanding (Basic)	36	34	24	16	8	Upgrade
Shares Outstanding (Diluted)	36	34	24	16	8	Upgrade
Shares Change	5.19%	42.27%	46.84%	104.93%	72.15%	Upgrade
EPS (Basic)	-1.91	-1.08	-0.96	-1.35	-2.49	Upgrade
EPS (Diluted)	-1.91	-1.08	-0.96	-1.35	-2.55	Upgrade
Free Cash Flow	-55.56	-34.69	-24.88	-19.09	-15.71	Upgrade
Free Cash Flow Per Share	-1.54	-1.01	-1.03	-1.16	-2.01	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	Upgrade
Operating Margin	-902.85%	-670.77%	-532.45%	-2622.96%	-	Upgrade
Profit Margin	-1524.51%	-670.24%	-517.55%	-2695.14%	-	Upgrade
Free Cash Flow Margin	-1226.69%	-629.85%	-556.08%	-2320.05%	-	Upgrade
EBITDA	-65.45	-36.03	-21.92	-20.44	-17.2	Upgrade
EBITDA Margin	-1445.07%	-654.05%	-489.99%	-2483.48%	-	Upgrade
Depreciation & Amortization	0.97	0.89	1.17	1.11	1.35	Upgrade
EBIT	-66.42	-36.92	-23.09	-21.55	-18.55	Upgrade
EBIT Margin	-1466.53%	-670.24%	-516.12%	-2618.83%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).